Latest news

• Novartis sales top £13bn in Q3 as the company reviews its generic business Sandoz

  Rejuvenation of our portfolio continues, from our key brands which include Kesimpta, Leqvio, Zolgensma and the oncology portfolio,” said Novartis CEO Vas Narasimhan.

• UK’s NICE recommends anti-cholesterol Leqvio for high-risk patients

  The decision follows the agreement of a “population-level commercial deal” between the NHS and Novartis to make Leqvio “available with a discount to its list price”, said NICE. ... Given as a twice-yearly injection and usually prescribed

• Novartis sees demand returning to pre-COVID-19 levels in Q2 results

  In the EU, inclisiran is already approved under the brand name Leqvio for the treatment of high cholesterol in patients with hypercholesterolemia or mixed dyslipidemia.

• Novartis announces delay in UK cholesterol drug study

  Swiss pharma company Novartis has readjusted the timings for a major study of its cholesterol drug Leqvio in the UK, after facing issues with recruitment due to the COVID-19 pandemic. ... Leqvio. “As we've seen both with COVID-19 and then the

• Novartis scores CHMP backing for cholesterol drug Leqvio

  Leqvio ( inclisiran) is a potential first-in-class treatment for high cholesterol in Europe for patients with hypercholesterolemia or mixed dyslipidemia. ... Novartis picked up Leqvio following its $9.7bn acquisition of The Medicines Company, which